Grace Tso1, Puja Kumar1, Thilini Jayasooriya2, Steve Kisely3, Dan Siskind4. 1. Registrar, Psychiatry, Metro South Addiction and Mental Health Service, Brisbane, QLD, Australia. 2. Registrar, Psychiatry, Metro South Addiction and Mental Health Service, Brisbane, QLD, Australia, and; District General Hospital Trincomalee, Trincomalee, Sri Lanka. 3. Professor, Psychiatry, Metro South Addiction and Mental Health Service, Brisbane, QLD, and; University of Queensland School of Medicine, Brisbane, QLD, Australia. 4. Associate Professor, Psychiatry, Metro South Addiction and Mental Health Service, Brisbane, QLD, and; University of Queensland School of Medicine, Brisbane, QLD, Australia.
Abstract
OBJECTIVE: To assess, among clozapine users, the rates of monitoring, presence and treatment of metabolic syndrome and its components. METHODS: A chart review was conducted of all clozapine users who were followed up in community mental health clinics at two Metro South Health Hospitals over a 1-year period. Metabolic syndrome was diagnosed according to the International Diabetes Federation criteria. RESULTS: We included 251 clozapine users. Only 43.4% (109/251) had data collected for all five metabolic syndrome parameters. Among these people, 45.0% (49/109) met criteria for metabolic syndrome, while 61.2% (30/49) of those with metabolic syndrome were offered appropriate treatments. Correspondence with primary care providers occurred in only 18.7% ( n = 47). Non-pharmacological interventions, such as motivational interviewing and education about healthy lifestyle alternatives, occurred in 49.8% ( n = 125). CONCLUSIONS: There is growing awareness of the importance of metabolic monitoring, however, there remain specific gaps in the collaborative work among mental health services, primary care providers and clozapine users, to ensure appropriate physical health interventions.
OBJECTIVE: To assess, among clozapine users, the rates of monitoring, presence and treatment of metabolic syndrome and its components. METHODS: A chart review was conducted of all clozapine users who were followed up in community mental health clinics at two Metro South Health Hospitals over a 1-year period. Metabolic syndrome was diagnosed according to the International Diabetes Federation criteria. RESULTS: We included 251 clozapine users. Only 43.4% (109/251) had data collected for all five metabolic syndrome parameters. Among these people, 45.0% (49/109) met criteria for metabolic syndrome, while 61.2% (30/49) of those with metabolic syndrome were offered appropriate treatments. Correspondence with primary care providers occurred in only 18.7% ( n = 47). Non-pharmacological interventions, such as motivational interviewing and education about healthy lifestyle alternatives, occurred in 49.8% ( n = 125). CONCLUSIONS: There is growing awareness of the importance of metabolic monitoring, however, there remain specific gaps in the collaborative work among mental health services, primary care providers and clozapine users, to ensure appropriate physical health interventions.
Authors: Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio Journal: Ther Adv Drug Saf Date: 2018-02-06
Authors: Ella Pearson; Dan Siskind; Ruth Hubbard; Emily Gordon; Elizabeth Coulson; Urska Arnautovska; Nicola Warren Journal: Community Ment Health J Date: 2022-07-05
Authors: Jessica Spokes; Samantha Hollingworth; Karl Winckel; Steve Kisely; Andrea Baker; Peter Cosgrove; Dan Siskind Journal: Ther Adv Psychopharmacol Date: 2021-03-16
Authors: Jessica W Y Yuen; David D Kim; Ric M Procyshyn; William J Panenka; William G Honer; Alasdair M Barr Journal: Front Endocrinol (Lausanne) Date: 2021-02-25 Impact factor: 5.555
Authors: Kenya A Costa-Dookhan; Tarek K Rajji; Veronica N Tran; Sylvie Bowden; Daniel J Mueller; Gary J Remington; Sri Mahavir Agarwal; Margaret K Hahn Journal: Sci Rep Date: 2021-01-21 Impact factor: 4.379
Authors: Jacqueline M Bailey; Kate M Bartlem; John H Wiggers; Paula M Wye; Emily A L Stockings; Rebecca K Hodder; Alexandra P Metse; Tim W Regan; Richard Clancy; Julia A Dray; Danika L Tremain; Tegan Bradley; Jenny A Bowman Journal: Prev Med Rep Date: 2019-08-14